<!doctype html>

<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Research • Stanfield Lab</title>
  <meta name="description" content="Stanfield Lab at LSU SVM: Developing guinea pig models for preclinical cancer drug and vaccine development.">
  <link rel="icon" href="assets/favicon.svg" type="image/svg+xml">
  <style>
    :root {
      --primary-blue: #0ea5e9;
      --primary-green: #10b981;
      --text-dark: #0f172a;
      --text-muted: #64748b;
      --bg-light: #f8fafc;
      --bg-card: #ffffff;
      --border-color: #e2e8f0;
      --shadow-md: 0 4px 6px -1px rgb(0 0 0 / 0.1);
      --accent-orange: #f59e0b;
      --accent-purple: #8b5cf6;
    }

* { box-sizing: border-box; }

body {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
  line-height: 1.6;
  color: var(--text-dark);
  background-color: var(--bg-light);
  margin: 0;
  padding: 0;
}

.container {
  max-width: 1200px;
  margin: 0 auto;
  padding: 0 1rem;
}

.site-header {
  background: var(--bg-card);
  border-bottom: 1px solid var(--border-color);
  box-shadow: 0 1px 3px 0 rgb(0 0 0 / 0.1);
  position: sticky;
  top: 0;
  z-index: 1000;
}

.header-wrap {
  display: flex;
  align-items: center;
  justify-content: space-between;
  padding: 1rem;
}

.brand {
  display: flex;
  align-items: center;
  text-decoration: none;
  color: var(--text-dark);
  font-weight: 700;
  font-size: 1.25rem;
}

.brand-img { height: 40px; margin-right: 0.5rem; }

nav { display: flex; align-items: center; }

.nav-toggle {
  display: none;
  background: none;
  border: none;
  font-size: 1rem;
  padding: 0.5rem;
  cursor: pointer;
}

.nav-list {
  display: flex;
  list-style: none;
  margin: 0;
  padding: 0;
  gap: 2rem;
}

.nav-list a {
  text-decoration: none;
  color: var(--text-dark);
  font-weight: 500;
  padding: 0.5rem 1rem;
  border-radius: 0.5rem;
  transition: all 0.2s;
}

.nav-list a:hover,
.nav-list a[aria-current="page"] {
  background-color: var(--bg-light);
  color: var(--primary-blue);
}

.theme-toggle {
  background: none;
  border: 1px solid var(--border-color);
  border-radius: 0.5rem;
  padding: 0.5rem;
  margin-left: 1rem;
  cursor: pointer;
  font-size: 1.2rem;
}

main { padding: 2rem 0; }

h1 {
  font-size: 3rem;
  font-weight: 800;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  background-clip: text;
  margin-bottom: 2rem;
  text-align: center;
}

h2 {
  font-size: 2rem;
  font-weight: 700;
  color: var(--text-dark);
  margin: 3rem 0 1.5rem 0;
  position: relative;
}

h2::after {
  content: '';
  position: absolute;
  bottom: -0.5rem;
  left: 0;
  width: 4rem;
  height: 3px;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  border-radius: 2px;
}

p {
  font-size: 1.05rem;
  line-height: 1.7;
  margin-bottom: 1.5rem;
}

.checklist {
  list-style: none;
  padding: 0;
  margin: 2rem 0;
}

.checklist li {
  background: var(--bg-card);
  border-radius: 0.75rem;
  padding: 1.5rem;
  margin-bottom: 1.5rem;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
  position: relative;
  transition: transform 0.2s ease;
  padding-left: 4rem;
}

.checklist li:hover { transform: translateY(-2px); }

.checklist li::before {
  content: '✓';
  position: absolute;
  left: 1.5rem;
  top: 1.5rem;
  color: var(--primary-green);
  font-weight: bold;
  font-size: 1.2rem;
}

.checklist li strong {
  color: var(--primary-blue);
  font-size: 1.1rem;
  display: block;
  margin-bottom: 0.5rem;
}

/* Diagram block */
.research-graphic {
  margin: 3rem auto;
  background: var(--bg-card);
  border-radius: 1rem;
  padding: 2rem;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
  position: relative;
}

.research-graphic h3 {
  font-size: 1.5rem;
  font-weight: 700;
  color: var(--primary-blue);
  margin: 0 0 1rem 0;
  text-align: center;
}

.static-svg {
  width: 100%;
  height: auto;
  display: block;
  margin: 0 auto;
}

.diagram-caption {
  background: var(--bg-light);
  border-radius: 0.5rem;
  padding: 1rem;
  margin-top: 1rem;
  text-align: center;
  font-size: 0.95rem;
  line-height: 1.5;
  color: var(--text-muted);
}

/* Research Impact / comparison */
.research-impact, .model-comparison {
  background: var(--bg-card);
  border-radius: 1rem;
  padding: 2rem;
  margin: 3rem 0;
  box-shadow: var(--shadow-md);
  border: 1px solid var(--border-color);
}

.impact-grid {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
  gap: 2rem;
  margin-top: 2rem;
}

.impact-card {
  background: var(--bg-light);
  border-radius: 0.75rem;
  padding: 1.5rem;
  text-align: center;
  transition: transform 0.2s ease;
}

.impact-card:hover { transform: translateY(-2px); }

.impact-number {
  font-size: 3rem;
  font-weight: 800;
  background: linear-gradient(135deg, var(--primary-blue), var(--primary-green));
  -webkit-background-clip: text;
  -webkit-text-fill-color: transparent;
  background-clip: text;
  display: block;
  margin-bottom: 0.5rem;
}

.impact-label { font-size: 1rem; color: var(--text-muted); font-weight: 500; }

.comparison-chart { margin: 2rem 0; }
.comparison-item { display: flex; align-items: center; margin: 1rem 0; padding: 1rem; background: var(--bg-light); border-radius: 0.5rem; }
.comparison-label { flex: 0 0 200px; font-weight: 600; color: var(--text-dark); }
.comparison-bars { flex: 1; display: flex; gap: 1rem; align-items: center; }
.comparison-bar { height: 24px; border-radius: 12px; display: flex; align-items: center; justify-content: center; color: white; font-size: 0.8rem; font-weight: 600; min-width: 60px; transition: transform 0.2s ease; }
.comparison-bar:hover { transform: scale(1.05); }
.bar-human { background: var(--primary-blue); }
.bar-guinea-pig { background: var(--primary-green); }
.bar-mouse { background: var(--text-muted); }

/* Motion & a11y */
.skip-link {
  position: absolute;
  top: -40px;
  left: 6px;
  background: var(--text-dark);
  color: white;
  padding: 8px;
  text-decoration: none;
  border-radius: 4px;
  z-index: 1001;
}
.skip-link:focus { top: 6px; }

.fade-in { opacity: 0; transform: translateY(20px); transition: all 0.6s ease; }
.fade-in.visible { opacity: 1; transform: translateY(0); }

/* Footer */
.site-footer { background: var(--text-dark); color: white; padding: 3rem 0 1rem; margin-top: 4rem; }
.footer-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 2rem; margin-bottom: 2rem; }
.footer-brand { display: flex; align-items: center; gap: 1rem; }
.footer-logo { height: 48px; }
.footer-brand h3 { margin: 0; font-size: 1.5rem; }
.footer-brand p { margin: 0.5rem 0 0 0; color: #94a3b8; font-size: 0.875rem; }
.footer-grid h4 { margin-bottom: 1rem; color: #e2e8f0; }
.footer-grid a { color: #94a3b8; text-decoration: none; }
.footer-grid a:hover { color: white; }
.footer-bottom { border-top: 1px solid #374151; padding-top: 1rem; text-align: center; color: #94a3b8; font-size: 0.875rem; }

/* Responsive */
@media (max-width: 768px) {
  .nav-toggle { display: block; }
  .nav-list {
    display: none; position: absolute; top: 100%; left: 0; right: 0; background: var(--bg-card);
    flex-direction: column; box-shadow: var(--shadow-md); border-top: 1px solid var(--border-color);
    padding: 1rem; gap: 0.5rem;
  }
  .nav-list.active { display: flex; }
  h1 { font-size: 2rem; }
  h2 { font-size: 1.5rem; }
  .research-graphic { padding: 1rem; margin: 2rem auto; }
  .impact-grid { grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); }
  .comparison-item { flex-direction: column; gap: 1rem; }
  .comparison-label { flex: none; text-align: center; }
  .comparison-bars { justify-content: center; }
}

@media (max-width: 480px) {
  .container { padding: 0 0.5rem; }
  .research-graphic { padding: 0.5rem; }
}

@media print {
  .site-header, .site-footer, .nav-toggle, .theme-toggle { display: none; }
  .research-graphic { break-inside: avoid; }
}

  </style>
</head>
<body>
  <a class="skip-link" href="#main">Skip to content</a>

  <header class="site-header" role="banner">
    <div class="container header-wrap">
      <a class="brand" href="index.html" aria-label="Stanfield Lab home">
        <img src="assets/stanfield-lab-logo.svg" alt="Stanfield Lab" class="brand-img">
      </a>
      <nav aria-label="Primary">
        <button id="navToggle" class="nav-toggle" aria-expanded="false" aria-controls="primaryNav">☰ Menu</button>
        <ul id="primaryNav" class="nav-list">
          <li><a href="index.html">Home</a></li>
          <li><a href="research.html" aria-current="page">Research</a></li>
          <li><a href="people.html">People</a></li>
          <li><a href="publications.html">Publications</a></li>
          <li><a href="news.html">News</a></li>
          <li><a href="Lab_Fun.html">Lab Fun</a></li>
          <li><a href="opportunities.html">Opportunities</a></li>
          <li><a href="contact.html">Contact</a></li>
        </ul>
      </nav>
      <button id="themeToggle" class="theme-toggle" aria-label="Toggle dark mode">◐</button>
    </div>
  </header>

  <main id="main" class="container">
    <h1 class="fade-in">Research</h1>

    <p class="fade-in">
      The Stanfield Lab investigates how oncogenic viruses initiate infection,
      evade host defenses, and drive cancer development. Our central mission is to
      create and refine <strong>immune-competent guinea pig models</strong> that bridge
      the gap between basic virology and translational medicine. By combining primary
      cell culture, in vivo pathogenesis studies, and advanced genomics, we aim to
      uncover how viruses such as <strong>Kaposi's sarcoma–associated herpesvirus (KSHV)</strong>,
      <strong>Epstein–Barr virus (EBV)</strong>, and <strong>Human papillomavirus (HPV)</strong> 
      establish infection and promote tumorigenesis.
    </p>

    <p class="fade-in">
      Guinea pigs provide a uniquely valuable system: their immune and physiological
      responses often parallel those of humans more closely than traditional murine
      models. We leverage this platform to model virus–host interactions, test
      therapeutic strategies, and expand the toolkit for studying host-restricted
      pathogens that have lacked tractable small-animal models. Our work spans from
      <strong>herpesvirus-associated lymphomas and sarcomas to HPV-driven cervical 
      cancers</strong>, providing comprehensive models for viral oncology research.
    </p>

    <!-- Impact -->
    <section class="research-impact fade-in">
      <h2>Research Impact</h2>
      <p>Our guinea pig models are advancing viral oncology across herpesvirus and papillomavirus-associated cancers, providing new tools for preclinical drug and vaccine development.</p>
    </section>

    <h2 class="fade-in">Current focus areas</h2>
    <ul class="checklist fade-in">
      <li><strong>Innate sensing and viral evasion.</strong> Defining how KSHV activates and subverts the <em>IRF7</em>, <em>MDA5</em>, and RIG-I pathways in guinea pig cells, and identifying viral genes that interfere with these sensors.</li>
      <li><strong>Endothelial infection and tumorigenesis.</strong> Establishing cultures of guinea pig endothelial cells and modeling how KSHV-driven transformation leads to vascularized tumors, both in immunodeficient mice and in immunosuppressed strain 2 guinea pigs.</li>
      <li><strong>HPV therapeutic vaccine development.</strong> Developing and testing therapeutic vaccines against HPV-associated cervical cancer using existing syngeneic mouse models while creating novel syngeneic guinea pig models that better recapitulate human disease.</li>
      <li><strong>Syngeneic guinea pig cervical cancer models.</strong> Engineering and characterizing new guinea pig models of HPV-associated cervical cancer for enhanced vaccine and therapeutic testing.</li>
      <li><strong>Syngeneic lymphoma model.</strong> Characterizing the L2C guinea pig lymphoma line with genomics and single-cell RNA-seq and positioning it as an analog for mantle cell lymphoma and CLL.</li>
      <li><strong>Comparative virology and viral adaptation.</strong> Studying related herpesviruses (RRV, GPHLV, GPXV) to guide engineering of guinea pig–adapted EBV and KSHV.</li>
      <li><strong>Preclinical testing platform.</strong> Evaluating antivirals, vaccines, epigenetic modulators, and targeted therapies (e.g., BTK inhibitors) across our models.</li>
      <li><strong>Single-cell and systems approaches.</strong> Applying scRNA-seq and pathway analysis to map viral/host programs and therapeutic responses in vivo.</li>
    </ul>

    <!-- Improved Diagram 1: Innate Immune Signaling -->
    <figure class="research-graphic fade-in">
      <h3>Innate Immune Signaling: Guinea Pig vs Human Responses to KSHV</h3>
      <svg class="static-svg" viewBox="0 0 1200 650" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Innate sensing via MDA5/MAVS/IRF7 in guinea pig vs human with KSHV antagonism">
        <defs>
          <marker id="arrG" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
          <marker id="arrN" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#9aa3af"/></marker>
          <marker id="tbar" viewBox="0 0 12 12" refX="2" refY="6" markerWidth="8" markerHeight="8" orient="auto"><path d="M2 0V12" stroke="#ef4444" stroke-width="3"/></marker>
          <filter id="soft"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
        </defs>
        
        <!-- Background panels -->
        <rect x="60" y="80" width="480" height="420" rx="20" fill="#ecfeff" stroke="#93c5fd" filter="url(#soft)"/>
        <rect x="660" y="80" width="480" height="420" rx="20" fill="#f8fafc" stroke="#cbd5e1" filter="url(#soft)"/>
        
        <!-- Headers -->
        <text x="300" y="50" text-anchor="middle" font-size="24" font-weight="700" fill="#0f172a">Guinea Pig — Activated</text>
        <text x="900" y="50" text-anchor="middle" font-size="24" font-weight="700" fill="#0f172a">Human — KSHV Suppression</text>
        
        <!-- Guinea pig pathway (left) -->
        <rect x="90" y="110" width="130" height="35" rx="10" fill="#e0f2fe" stroke="#0ea5e9"/>
        <text x="155" y="132" text-anchor="middle" font-weight="600" fill="#075985">dsRNA (viral)</text>
        
        <rect x="280" y="110" width="120" height="35" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="340" y="132" text-anchor="middle" font-weight="700" fill="#065f46">MDA5</text>
        
        <rect x="280" y="170" width="120" height="35" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="340" y="192" text-anchor="middle" font-weight="700" fill="#065f46">MAVS</text>
        
        <rect x="280" y="230" width="120" height="35" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="340" y="252" text-anchor="middle" font-weight="700" fill="#065f46">IRF7</text>
        
        <rect x="280" y="290" width="120" height="35" rx="12" fill="#10b981" stroke="#059669"/>
        <text x="340" y="312" text-anchor="middle" font-weight="700" fill="#fff">Type I IFN</text>
        
        <!-- Guinea pig pathway arrows -->
        <line x1="220" y1="127" x2="275" y2="127" stroke="#10b981" stroke-width="4" marker-end="url(#arrG)"/>
        <line x1="340" y1="145" x2="340" y2="165" stroke="#10b981" stroke-width="4" marker-end="url(#arrG)"/>
        <line x1="340" y1="205" x2="340" y2="225" stroke="#10b981" stroke-width="4" marker-end="url(#arrG)"/>
        <line x1="340" y1="265" x2="340" y2="285" stroke="#10b981" stroke-width="4" marker-end="url(#arrG)"/>
        
        <!-- KSHV interference boxes (Guinea pig) -->
        <rect x="430" y="105" width="140" height="50" rx="8" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="500" y="122" text-anchor="middle" font-size="12" font-weight="600" fill="#92400e">KSHV miRNAs</text>
        <text x="500" y="136" text-anchor="middle" font-size="10" fill="#92400e">Seed mismatch</text>
        <text x="500" y="148" text-anchor="middle" font-size="10" fill="#92400e">→ Weak inhibition</text>
        
        <rect x="430" y="225" width="140" height="50" rx="8" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="500" y="242" text-anchor="middle" font-size="12" font-weight="600" fill="#92400e">vIRF-3 (K10.5)</text>
        <text x="500" y="256" text-anchor="middle" font-size="10" fill="#92400e">Poor GP IRF7 binding</text>
        <text x="500" y="268" text-anchor="middle" font-size="10" fill="#92400e">→ Reduced inhibition</text>
        
        <!-- Weak inhibition arrows -->
        <path d="M 430 130 Q 410 130 400 127" stroke="#f59e0b" stroke-width="2" fill="none" stroke-dasharray="4,2"/>
        <path d="M 430 250 Q 410 250 400 252" stroke="#f59e0b" stroke-width="2" fill="none" stroke-dasharray="4,2"/>
        
        <!-- Human pathway (right) -->
        <rect x="690" y="110" width="120" height="35" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/>
        <text x="750" y="132" text-anchor="middle" font-weight="600" fill="#374151">MDA5</text>
        
        <rect x="690" y="170" width="120" height="35" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/>
        <text x="750" y="192" text-anchor="middle" font-weight="600" fill="#374151">MAVS</text>
        
        <rect x="690" y="230" width="120" height="35" rx="12" fill="#e5e7eb" stroke="#cbd5e1"/>
        <text x="750" y="252" text-anchor="middle" font-weight="600" fill="#374151">IRF7</text>
        
        <rect x="690" y="290" width="120" height="35" rx="12" fill="#d1d5db" stroke="#cbd5e1"/>
        <text x="750" y="312" text-anchor="middle" font-weight="600" fill="#111827">Type I IFN ↓</text>
        
        <!-- Human pathway arrows (suppressed) -->
        <line x1="750" y1="145" x2="750" y2="165" stroke="#9aa3af" stroke-width="3" marker-end="url(#arrN)"/>
        <line x1="750" y1="205" x2="750" y2="225" stroke="#9aa3af" stroke-width="3" marker-end="url(#arrN)"/>
        <line x1="750" y1="265" x2="750" y2="285" stroke="#9aa3af" stroke-width="3" marker-end="url(#arrN)"/>
        
        <!-- KSHV strong interference (Human) -->
        <rect x="850" y="105" width="160" height="50" rx="8" fill="#fee2e2" stroke="#ef4444"/>
        <text x="930" y="122" text-anchor="middle" font-size="12" font-weight="700" fill="#991b1b">KSHV miRNAs</text>
        <text x="930" y="136" text-anchor="middle" font-size="10" fill="#991b1b">Target IFIH1 (MDA5)</text>
        <text x="930" y="148" text-anchor="middle" font-size="10" fill="#991b1b">→ Strong repression</text>
        
        <rect x="850" y="225" width="160" height="50" rx="8" fill="#fee2e2" stroke="#ef4444"/>
        <text x="930" y="242" text-anchor="middle" font-size="12" font-weight="700" fill="#991b1b">vIRF-3 (K10.5)</text>
        <text x="930" y="256" text-anchor="middle" font-size="10" fill="#991b1b">Binds and blocks IRF7</text>
        <text x="930" y="268" text-anchor="middle" font-size="10" fill="#991b1b">→ Effective inhibition</text>
        
        <!-- Strong inhibition arrows -->
        <line x1="850" y1="130" x2="815" y2="127" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
        <line x1="850" y1="250" x2="815" y2="252" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
        
        <!-- Summary box -->
        <rect x="60" y="530" width="1080" height="90" rx="12" fill="#f1f5f9" stroke="#cbd5e1"/>
        <text x="80" y="555" font-weight="700" font-size="14" fill="#0f172a">Summary:</text>
        <text x="80" y="575" fill="#334155" font-size="12">
          Guinea pig cells maintain stronger innate immunity against KSHV due to sequence mismatches that reduce
        </text>
        <text x="80" y="590" fill="#334155" font-size="12">
          viral miRNA efficacy and altered protein-protein interactions that weaken vIRF-3 inhibition of IRF7.
        </text>
        <text x="80" y="605" fill="#334155" font-size="12">
          This results in preserved MDA5→MAVS→IRF7→Type I IFN signaling compared to strong suppression in human cells.
        </text>
      </svg>
      <div class="diagram-caption">
        Guinea pig cells show enhanced MDA5→MAVS→IRF7 activation due to reduced KSHV miRNA and vIRF-3 inhibition compared to human cells.
      </div>
    </figure>

    <!-- Improved Diagram 2: KSHV Endothelial Transformation -->
    <figure class="research-graphic fade-in">
      <h3>KSHV Endothelial Cell Transformation and Kaposi's Sarcoma Development</h3>
      <svg class="static-svg" viewBox="0 0 1200 600" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="KSHV endothelial transformation pathway">
        <defs>
          <marker id="arrBlue2" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#0ea5e9"/></marker>
          <marker id="arrRed2" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
          <marker id="arrGreen2" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
        </defs>
        
        <!-- Entry stage -->
        <rect x="60" y="80" width="200" height="80" rx="12" fill="#eef2ff" stroke="#6366f1"/>
        <text x="160" y="105" text-anchor="middle" font-size="16" font-weight="700" fill="#3730a3">Entry & Attachment</text>
        <text x="160" y="125" text-anchor="middle" font-size="12" fill="#3730a3">Heparan sulfate</text>
        <text x="160" y="140" text-anchor="middle" font-size="12" fill="#3730a3">Integrins (αVβ3, α3β1)</text>
        <text x="160" y="155" text-anchor="middle" font-size="12" fill="#3730a3">EphA2, DC-SIGN</text>
        
        <!-- Acute signaling -->
        <rect x="300" y="80" width="200" height="80" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
        <text x="400" y="105" text-anchor="middle" font-size="16" font-weight="700" fill="#075985">Acute Signaling</text>
        <text x="400" y="125" text-anchor="middle" font-size="12" fill="#075985">FAK/Src → PI3K-AKT</text>
        <text x="400" y="140" text-anchor="middle" font-size="12" fill="#075985">MAPK/ERK activation</text>
        <text x="400" y="155" text-anchor="middle" font-size="12" fill="#075985">NF-κB survival signals</text>
        
        <!-- Latency programs -->
        <rect x="540" y="80" width="280" height="80" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="680" y="105" text-anchor="middle" font-size="16" font-weight="700" fill="#92400e">Latency Programs</text>
        <!-- Latency genes -->
        <rect x="560" y="120" width="60" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="590" y="137" text-anchor="middle" font-size="11" font-weight="600" fill="#9a3412">LANA</text>
        
        <rect x="630" y="120" width="70" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="665" y="137" text-anchor="middle" font-size="10" font-weight="600" fill="#9a3412">vCyclin</text>
        
        <rect x="710" y="120" width="50" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="735" y="137" text-anchor="middle" font-size="11" font-weight="600" fill="#9a3412">vFLIP</text>
        
        <rect x="770" y="120" width="40" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="790" y="137" text-anchor="middle" font-size="11" font-weight="600" fill="#9a3412">K1</text>
        
        <!-- Paracrine factors -->
        <rect x="60" y="200" width="220" height="80" rx="12" fill="#fff7ed" stroke="#fb923c"/>
        <text x="170" y="225" text-anchor="middle" font-size="16" font-weight="700" fill="#9a3412">Paracrine Factors</text>
        <rect x="80" y="245" width="50" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="105" y="262" text-anchor="middle" font-size="11" font-weight="600" fill="#9a3412">vIL-6</text>
        
        <rect x="140" y="245" width="60" height="25" rx="5" fill="#fed7aa" stroke="#ea580c"/>
        <text x="170" y="262" text-anchor="middle" font-size="10" font-weight="600" fill="#9a3412">vGPCR</text>
        
        <rect x="210" y="245" width="50" height="25" rx="5" fill="#fee2e2" stroke="#ef4444"/>
        <text x="235" y="262" text-anchor="middle" font-size="11" font-weight="600" fill="#991b1b">VEGF</text>
        
        <!-- KS lesion -->
        <rect x="320" y="200" width="220" height="80" rx="12" fill="#ffe4e6" stroke="#fb7185"/>
        <text x="430" y="225" text-anchor="middle" font-size="16" font-weight="700" fill="#9f1239">KS-like Lesion</text>
        <text x="430" y="245" text-anchor="middle" font-size="12" fill="#9f1239">Spindle cell morphology</text>
        <text x="430" y="260" text-anchor="middle" font-size="12" fill="#9f1239">Vascular architecture</text>
        <text x="430" y="275" text-anchor="middle" font-size="12" fill="#9f1239">Inflammatory infiltrate</text>
        
        <!-- Hallmarks -->
        <rect x="580" y="200" width="240" height="120" rx="12" fill="#f1f5f9" stroke="#cbd5e1"/>
        <text x="700" y="225" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Oncogenic Hallmarks</text>
        <text x="700" y="250" text-anchor="middle" font-size="12" fill="#334155">• Enhanced angiogenesis (VEGF/HIF-1α)</text>
        <text x="700" y="270" text-anchor="middle" font-size="12" fill="#334155">• Deregulated proliferation (vCyclin-CDK6)</text>
        <text x="700" y="290" text-anchor="middle" font-size="12" fill="#334155">• Survival signaling (vFLIP → NF-κB)</text>
        <text x="700" y="310" text-anchor="middle" font-size="12" fill="#334155">• Immune evasion (viral miRNAs)</text>
        
        <!-- Flow arrows -->
        <line x1="260" y1="120" x2="295" y2="120" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrBlue2)"/>
        <line x1="500" y1="120" x2="535" y2="120" stroke="#f59e0b" stroke-width="4" marker-end="url(#arrBlue2)"/>
        <line x1="680" y1="160" x2="430" y2="195" stroke="#ef4444" stroke-width="3" marker-end="url(#arrRed2)"/>
        <line x1="280" y1="240" x2="315" y2="240" stroke="#fb923c" stroke-width="4" marker-end="url(#arrRed2)"/>
        <line x1="540" y1="240" x2="575" y2="240" stroke="#334155" stroke-width="3" marker-end="url(#arrBlue2)"/>
        
        <!-- Summary -->
        <rect x="60" y="360" width="760" height="80" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="80" y="385" font-weight="700" fill="#0f172a">Transformation pathway:</text>
        <text x="80" y="405" fill="#334155" font-size="12">KSHV entry via multiple receptors activates survival pathways (PI3K-AKT, NF-κB). Latency genes</text>
        <text x="80" y="420" fill="#334155" font-size="12">LANA, vCyclin, vFLIP, and K1 drive transformation while paracrine factors (vIL-6, vGPCR, VEGF)</text>
        <text x="80" y="435" fill="#334155" font-size="12">promote angiogenesis and immune evasion, resulting in characteristic KS-like vascular lesions.</text>
      </svg>
      <div class="diagram-caption">
        KSHV endothelial transformation progresses through receptor engagement, acute signaling, latency establishment, and paracrine-driven angiogenesis.
      </div>
    </figure>

    <!-- Improved Diagram 3: HPV Cervical Cancer -->
    <figure class="research-graphic fade-in">
      <h3>HPV Cervical Cancer Progression and Therapeutic Vaccine Strategy</h3>
      <svg class="static-svg" viewBox="0 0 1200 600" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="HPV progression and therapeutic vaccination">
        <defs>
          <marker id="arrHPV" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
          <marker id="arrOrange3" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
          <marker id="arrBlue3" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
          <marker id="arrGreen3" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
        </defs>
        
        <!-- Normal cervix -->
        <rect x="60" y="300" width="140" height="100" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="130" y="325" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Normal Cervical</text>
        <text x="130" y="345" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Epithelium</text>
        <text x="130" y="365" text-anchor="middle" font-size="11" fill="#065f46">Stratified squamous</text>
        <text x="130" y="380" text-anchor="middle" font-size="11" fill="#065f46">Normal differentiation</text>
        
        <!-- HPV infection -->
        <circle cx="130" cy="220" r="30" fill="#a855f7" stroke="#7c3aed"/>
        <text x="130" y="215" text-anchor="middle" font-size="12" font-weight="700" fill="#fff">HPV</text>
        <text x="130" y="230" text-anchor="middle" font-size="11" fill="#fff">16/18</text>
        
        <!-- E6/E7 oncoproteins -->
        <rect x="90" y="120" width="80" height="50" rx="8" fill="#fee2e2" stroke="#ef4444"/>
        <text x="130" y="138" text-anchor="middle" font-size="13" font-weight="700" fill="#991b1b">E6/E7</text>
        <text x="130" y="152" text-anchor="middle" font-size="10" fill="#991b1b">E6 → p53 ↓</text>
        <text x="130" y="164" text-anchor="middle" font-size="10" fill="#991b1b">E7 → pRb ↓</text>
        
        <!-- Disease progression -->
        <rect x="250" y="300" width="140" height="100" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="320" y="325" text-anchor="middle" font-size="14" font-weight="700" fill="#92400e">CIN 1</text>
        <text x="320" y="345" text-anchor="middle" font-size="12" font-weight="700" fill="#92400e">Low-grade</text>
        <text x="320" y="365" text-anchor="middle" font-size="11" fill="#92400e">Mild dysplasia</text>
        <text x="320" y="380" text-anchor="middle" font-size="11" fill="#92400e">Often reversible</text>
        
        <rect x="440" y="300" width="140" height="100" rx="12" fill="#fed7aa" stroke="#ea580c"/>
        <text x="510" y="325" text-anchor="middle" font-size="14" font-weight="700" fill="#9a3412">CIN 2/3</text>
        <text x="510" y="345" text-anchor="middle" font-size="12" font-weight="700" fill="#9a3412">High-grade</text>
        <text x="510" y="365" text-anchor="middle" font-size="11" fill="#9a3412">Severe dysplasia</text>
        <text x="510" y="380" text-anchor="middle" font-size="11" fill="#9a3412">Precancerous</text>
        
        <rect x="630" y="300" width="140" height="100" rx="12" fill="#fee2e2" stroke="#dc2626"/>
        <text x="700" y="320" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">Invasive</text>
        <text x="700" y="340" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">Cervical</text>
        <text x="700" y="360" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">Carcinoma</text>
        <text x="700" y="380" text-anchor="middle" font-size="11" fill="#991b1b">Invasive disease</text>
        
        <!-- Animal models -->
        <rect x="60" y="80" width="140" height="60" rx="12" fill="#e5e7eb" stroke="#6b7280"/>
        <text x="130" y="100" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Mouse Models</text>
        <text x="130" y="120" text-anchor="middle" font-size="11" fill="#374151">TC-1, C3-Tag</text>
        
        <rect x="250" y="80" width="160" height="60" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="330" y="100" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Guinea Pig Models</text>
        <text x="330" y="120" text-anchor="middle" font-size="11" fill="#065f46">Enhanced human similarity</text>
        
        <!-- Therapeutic vaccine -->
        <rect x="850" y="180" width="160" height="120" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
        <text x="930" y="205" text-anchor="middle" font-size="14" font-weight="700" fill="#1d4ed8">E6/E7 Therapeutic</text>
        <text x="930" y="225" text-anchor="middle" font-size="14" font-weight="700" fill="#1d4ed8">Vaccine</text>
        <text x="930" y="250" text-anchor="middle" font-size="11" fill="#1d4ed8">• Target existing lesions</text>
        <text x="930" y="265" text-anchor="middle" font-size="11" fill="#1d4ed8">• CD8+ T cell responses</text>
        <text x="930" y="280" text-anchor="middle" font-size="11" fill="#1d4ed8">• Tumor regression</text>
        <text x="930" y="295" text-anchor="middle" font-size="11" fill="#1d4ed8">• Prevention of recurrence</text>
        
        <!-- Immune response -->
        <rect x="850" y="340" width="160" height="80" rx="12" fill="#ecfdf5" stroke="#10b981"/>
        <text x="930" y="365" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Immune Activation</text>
        <text x="930" y="385" text-anchor="middle" font-size="11" fill="#065f46">CTL clearance</text>
        <text x="930" y="400" text-anchor="middle" font-size="11" fill="#065f46">Memory formation</text>
        
        <!-- Progression arrows -->
        <line x1="130" y1="250" x2="130" y2="295" stroke="#8b5cf6" stroke-width="4" marker-end="url(#arrHPV)"/>
        <line x1="130" y1="170" x2="130" y2="190" stroke="#ef4444" stroke-width="3" marker-end="url(#arrHPV)"/>
        <line x1="200" y1="350" x2="245" y2="350" stroke="#f59e0b" stroke-width="4" marker-end="url(#arrOrange3)"/>
        <line x1="390" y1="350" x2="435" y2="350" stroke="#ea580c" stroke-width="4" marker-end="url(#arrOrange3)"/>
        <line x1="580" y1="350" x2="625" y2="350" stroke="#dc2626" stroke-width="4" marker-end="url(#arrOrange3)"/>
        
        <!-- Vaccine intervention -->
        <path d="M 850 240 Q 800 280 700 300" stroke="#3b82f6" stroke-width="3" fill="none" stroke-dasharray="8,4" marker-end="url(#arrBlue3)"/>
        <path d="M 850 240 Q 780 270 510 300" stroke="#3b82f6" stroke-width="3" fill="none" stroke-dasharray="8,4" marker-end="url(#arrBlue3)"/>
        
        <!-- Model enhancement -->
        <line x1="210" y1="110" x2="245" y2="110" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen3)"/>
        
        <!-- Immune response connection -->
        <line x1="930" y1="300" x2="930" y2="335" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen3)"/>
        
        <!-- Summary -->
        <rect x="60" y="480" width="950" height="80" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="80" y="505" font-weight="700" fill="#0f172a">Therapeutic strategy:</text>
        <text x="80" y="525" fill="#334155" font-size="12">HPV E6/E7 oncoproteins drive progression from normal cervix through CIN to invasive carcinoma.</text>
        <text x="80" y="540" fill="#334155" font-size="12">E6/E7-targeted therapeutic vaccines tested in mouse models (TC-1, C3-Tag) and novel guinea pig</text>
        <text x="80" y="555" fill="#334155" font-size="12">models activate CD8+ T cells to clear existing lesions and prevent progression to invasive disease.</text>
      </svg>
      <div class="diagram-caption">
        HPV E6/E7-driven cervical cancer progression with therapeutic vaccine intervention targeting existing lesions and preventing recurrence.
      </div>
    </figure>

    <!-- Improved Diagram 4: L2C Lymphoma Model -->
    <figure class="research-graphic fade-in">
      <h3>L2C Guinea Pig Lymphoma Model for Therapeutic Development</h3>
      <svg class="static-svg" viewBox="0 0 1200 600" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="L2C lymphoma model and BTK inhibitor testing">
        <defs>
          <marker id="arrBlue4" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
          <marker id="arrRed4" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
          <marker id="arrGreen4" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
          <marker id="arrPurple4" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
        </defs>
        
        <!-- Normal B cell -->
        <circle cx="120" cy="150" r="40" fill="#dcfce7" stroke="#10b981"/>
        <text x="120" y="145" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Normal</text>
        <text x="120" y="160" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">B Cell</text>
        
        <!-- L2C lymphoma cell -->
        <circle cx="320" cy="150" r="45" fill="#fecaca" stroke="#ef4444"/>
        <text x="320" y="140" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">L2C</text>
        <text x="320" y="155" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">Lymphoma</text>
        <text x="320" y="170" text-anchor="middle" font-size="11" fill="#991b1b">Malignant B cells</text>
        
        <!-- BCR signaling -->
        <rect x="220" y="80" width="200" height="50" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
        <text x="320" y="100" text-anchor="middle" font-size="14" font-weight="700" fill="#075985">BCR → BTK → NF-κB</text>
        <text x="320" y="118" text-anchor="middle" font-size="11" fill="#075985">Survival addiction pathway</text>
        
        <!-- Guinea pig model -->
        <rect x="500" y="120" width="200" height="80" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="600" y="145" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Syngeneic GP Model</text>
        <text x="600" y="165" text-anchor="middle" font-size="11" fill="#065f46">• Strain 2 guinea pigs</text>
        <text x="600" y="180" text-anchor="middle" font-size="11" fill="#065f46">• Immune competent</text>
        <text x="600" y="195" text-anchor="middle" font-size="11" fill="#065f46">• Tumor growth kinetics</text>
        
        <!-- Single-cell analysis -->
        <rect x="750" y="80" width="180" height="80" rx="12" fill="#faf5ff" stroke="#8b5cf6"/>
        <text x="840" y="105" text-anchor="middle" font-size="14" font-weight="700" fill="#6b21a8">Single-cell Analysis</text>
        <text x="840" y="125" text-anchor="middle" font-size="11" fill="#6b21a8">• scRNA-seq profiling</text>
        <text x="840" y="140" text-anchor="middle" font-size="11" fill="#6b21a8">• Genomic characterization</text>
        <text x="840" y="155" text-anchor="middle" font-size="11" fill="#6b21a8">• Drug response signatures</text>
        
        <!-- Human disease analogs -->
        <rect x="80" y="280" width="140" height="60" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
        <text x="150" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#374151">Mantle Cell</text>
        <text x="150" y="320" text-anchor="middle" font-size="13" font-weight="700" fill="#374151">Lymphoma</text>
        
        <rect x="260" y="280" width="140" height="60" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
        <text x="330" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#374151">Chronic Lymphocytic</text>
        <text x="330" y="320" text-anchor="middle" font-size="13" font-weight="700" fill="#374151">Leukemia</text>
        
        <!-- BTK inhibitors -->
        <rect x="450" y="280" width="280" height="100" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
        <text x="590" y="305" text-anchor="middle" font-size="14" font-weight="700" fill="#1d4ed8">BTK Inhibitor Testing</text>
        
        <rect x="470" y="320" width="70" height="25" rx="5" fill="#bfdbfe" stroke="#3b82f6"/>
        <text x="505" y="337" text-anchor="middle" font-size="10" font-weight="600" fill="#1d4ed8">Ibrutinib</text>
        
        <rect x="550" y="320" width="80" height="25" rx="5" fill="#bfdbfe" stroke="#3b82f6"/>
        <text x="590" y="337" text-anchor="middle" font-size="10" font-weight="600" fill="#1d4ed8">Acalabrutinib</text>
        
        <rect x="640" y="320" width="80" height="25" rx="5" fill="#bfdbfe" stroke="#3b82f6"/>
        <text x="680" y="337" text-anchor="middle" font-size="9" font-weight="600" fill="#1d4ed8">Zanubrutinib</text>
        
        <rect x="470" y="350" width="120" height="25" rx="5" fill="#bfdbfe" stroke="#3b82f6"/>
        <text x="530" y="367" text-anchor="middle" font-size="10" font-weight="600" fill="#1d4ed8">Next-generation</text>
        
        <!-- Outcomes -->
        <rect x="780" y="280" width="140" height="80" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="850" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Outcomes</text>
        <text x="850" y="325" text-anchor="middle" font-size="11" fill="#92400e">• Efficacy</text>
        <text x="850" y="340" text-anchor="middle" font-size="11" fill="#92400e">• Toxicity</text>
        <text x="850" y="355" text-anchor="middle" font-size="11" fill="#92400e">• Resistance</text>
        
        <!-- Transformation arrow -->
        <line x1="165" y1="150" x2="275" y2="150" stroke="#ef4444" stroke-width="4" marker-end="url(#arrRed4)"/>
        <text x="220" y="140" text-anchor="middle" font-size="11" fill="#ef4444" font-weight="600">Transformation</text>
        
        <!-- BCR signaling -->
        <line x1="320" y1="130" x2="320" y2="110" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlue4)"/>
        
        <!-- Model inoculation -->
        <line x1="365" y1="150" x2="495" y2="150" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen4)"/>
        <text x="430" y="140" text-anchor="middle" font-size="11" fill="#10b981" font-weight="600">Inoculation</text>
        
        <!-- Analysis connection -->
        <line x1="700" y1="160" x2="745" y2="120" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurple4)"/>
        <text x="725" y="135" text-anchor="middle" font-size="10" fill="#8b5cf6" font-weight="600">Profile</text>
        
        <!-- Human disease modeling -->
        <path d="M 320 195 Q 220 240 150 280" stroke="#6b7280" stroke-width="2" fill="none" stroke-dasharray="5,3"/>
        <path d="M 320 195 Q 325 240 330 280" stroke="#6b7280" stroke-width="2" fill="none" stroke-dasharray="5,3"/>
        <text x="235" y="240" text-anchor="middle" font-size="10" fill="#6b7280" font-weight="600">Models</text>
        
        <!-- Drug testing -->
        <line x1="600" y1="200" x2="590" y2="275" stroke="#3b82f6" stroke-width="3" marker-end="url(#arrBlue4)"/>
        <line x1="730" y1="330" x2="775" y2="330" stroke="#f59e0b" stroke-width="3" marker-end="url(#arrBlue4)"/>
        
        <!-- Summary -->
        <rect x="80" y="420" width="850" height="80" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="100" y="445" font-weight="700" fill="#0f172a">L2C model advantages:</text>
        <text x="100" y="465" fill="#334155" font-size="12">Syngeneic guinea pig B-cell lymphoma with BCR→BTK→NF-κB addiction enables comprehensive</text>
        <text x="100" y="480" fill="#334155" font-size="12">BTK inhibitor pharmacology. Single-cell genomics positions L2C as analog for human MCL</text>
        <text x="100" y="495" fill="#334155" font-size="12">and CLL, providing immune-competent platform for preclinical therapeutic evaluation.</text>
      </svg>
      <div class="diagram-caption">
        L2C model with BCR→BTK→NF-κB signaling addiction enables BTK inhibitor testing with single-cell profiling and human disease correlation.
      </div>
    </figure>

    <!-- Improved Diagram 5: Comparative Virology (with corrected GPXV) -->
    <figure class="research-graphic fade-in">
      <h3>Comparative Virology and Host Adaptation Engineering</h3>
      <svg class="static-svg" viewBox="0 0 1200 650" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Comparative virology approach for host adaptation">
        <defs>
          <marker id="arrBlue5" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
          <marker id="arrOrange5" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
          <marker id="arrGreen5" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
          <marker id="arrPurple5" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
        </defs>
        
        <!-- Human-restricted viruses -->
        <text x="150" y="40" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Human-Restricted Viruses</text>
        
        <circle cx="100" cy="80" r="35" fill="#fecaca" stroke="#ef4444"/>
        <text x="100" y="75" text-anchor="middle" font-size="12" font-weight="700" fill="#991b1b">KSHV</text>
        <text x="100" y="90" text-anchor="middle" font-size="10" fill="#991b1b">(HHV-8)</text>
        
        <circle cx="200" cy="80" r="35" fill="#fecaca" stroke="#ef4444"/>
        <text x="200" y="75" text-anchor="middle" font-size="12" font-weight="700" fill="#991b1b">EBV</text>
        <text x="200" y="90" text-anchor="middle" font-size="10" fill="#991b1b">(HHV-4)</text>
        
        <!-- Related animal viruses -->
        <text x="150" y="200" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Related Animal Viruses</text>
        
        <circle cx="80" cy="250" r="30" fill="#fed7aa" stroke="#f59e0b"/>
        <text x="80" y="245" text-anchor="middle" font-size="11" font-weight="700" fill="#92400e">RRV</text>
        <text x="80" y="260" text-anchor="middle" font-size="9" fill="#92400e">Rhesus</text>
        
        <circle cx="150" cy="250" r="30" fill="#fed7aa" stroke="#f59e0b"/>
        <text x="150" y="245" text-anchor="middle" font-size="10" font-weight="700" fill="#92400e">GPHLV</text>
        <text x="150" y="260" text-anchor="middle" font-size="8" fill="#92400e">GP herpes-like</text>
        
        <circle cx="220" cy="250" r="30" fill="#fed7aa" stroke="#f59e0b"/>
        <text x="220" y="245" text-anchor="middle" font-size="11" font-weight="700" fill="#92400e">GPXV</text>
        <text x="220" y="260" text-anchor="middle" font-size="9" fill="#92400e">GP X virus</text>
        
        <!-- Engineering process -->
        <rect x="350" y="120" width="280" height="160" rx="12" fill="#f3e8ff" stroke="#8b5cf6"/>
        <text x="490" y="145" text-anchor="middle" font-size="16" font-weight="700" fill="#6b21a8">Adaptation Engineering</text>
        
        <!-- Key factors -->
        <rect x="370" y="160" width="120" height="50" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="430" y="180" text-anchor="middle" font-size="12" font-weight="700" fill="#6b21a8">Host Tropism</text>
        <text x="430" y="195" text-anchor="middle" font-size="10" fill="#6b21a8">Receptor binding</text>
        <text x="430" y="207" text-anchor="middle" font-size="10" fill="#6b21a8">Entry mechanisms</text>
        
        <rect x="500" y="160" width="120" height="50" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="560" y="180" text-anchor="middle" font-size="12" font-weight="700" fill="#6b21a8">Immune Evasion</text>
        <text x="560" y="195" text-anchor="middle" font-size="10" fill="#6b21a8">Species-specific vIRFs</text>
        <text x="560" y="207" text-anchor="middle" font-size="10" fill="#6b21a8">miRNA seed matches</text>
        
        <rect x="370" y="220" width="240" height="50" rx="8" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="490" y="240" text-anchor="middle" font-size="12" font-weight="700" fill="#6b21a8">Engineering Strategy</text>
        <text x="490" y="255" text-anchor="middle" font-size="10" fill="#6b21a8">Modify receptor binding domains, immune evasion genes</text>
        <text x="490" y="267" text-anchor="middle" font-size="10" fill="#6b21a8">Optimize for guinea pig host factors</text>
        
        <!-- Engineered viruses -->
        <text x="850" y="40" text-anchor="middle" font-size="16" font-weight="700" fill="#0f172a">Guinea Pig-Adapted</text>
        
        <circle cx="800" cy="80" r="35" fill="#dcfce7" stroke="#10b981"/>
        <text x="800" y="70" text-anchor="middle" font-size="11" font-weight="700" fill="#065f46">KSHV-GP</text>
        <text x="800" y="85" text-anchor="middle" font-size="9" fill="#065f46">Engineered</text>
        <text x="800" y="95" text-anchor="middle" font-size="9" fill="#065f46">strain</text>
        
        <circle cx="900" cy="80" r="35" fill="#dcfce7" stroke="#10b981"/>
        <text x="900" y="70" text-anchor="middle" font-size="11" font-weight="700" fill="#065f46">EBV-GP</text>
        <text x="900" y="85" text-anchor="middle" font-size="9" fill="#065f46">Engineered</text>
        <text x="900" y="95" text-anchor="middle" font-size="9" fill="#065f46">strain</text>
        
        <!-- Guinea pig host -->
        <rect x="700" y="150" width="220" height="100" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="810" y="175" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">Guinea Pig Host System</text>
        <text x="810" y="195" text-anchor="middle" font-size="11" fill="#065f46">• Immune competent</text>
        <text x="810" y="210" text-anchor="middle" font-size="11" fill="#065f46">• Enhanced human similarity</text>
        <text x="810" y="225" text-anchor="middle" font-size="11" fill="#065f46">• Pathogenesis studies</text>
        <text x="810" y="240" text-anchor="middle" font-size="11" fill="#065f46">• Therapeutic testing</text>
        
        <!-- Validation -->
        <rect x="350" y="320" width="280" height="80" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
        <text x="490" y="345" text-anchor="middle" font-size="14" font-weight="700" fill="#075985">In Vivo Validation</text>
        <text x="490" y="365" text-anchor="middle" font-size="11" fill="#075985">• Infection kinetics and tropism</text>
        <text x="490" y="380" text-anchor="middle" font-size="11" fill="#075985">• Pathogenesis patterns</text>
        <text x="490" y="395" text-anchor="middle" font-size="11" fill="#075985">• Immune responses and clearance</text>
        
        <!-- Flow arrows -->
        <line x1="240" y1="80" x2="345" y2="150" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurple5)"/>
        <text x="290" y="110" text-anchor="middle" font-size="10" fill="#8b5cf6" font-weight="600">Analysis</text>
        
        <line x1="630" y1="200" x2="695" y2="80" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen5)"/>
        <text x="665" y="140" text-anchor="middle" font-size="10" fill="#10b981" font-weight="600">Engineer</text>
        
        <path d="M 150 280 Q 270 300 350 250" stroke="#f59e0b" stroke-width="3" fill="none" stroke-dasharray="6,3"/>
        <text x="250" y="300" text-anchor="middle" font-size="10" fill="#f59e0b" font-weight="600">Insights</text>
        
        <line x1="810" y1="115" x2="810" y2="145" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen5)"/>
        
        <line x1="490" y1="280" x2="490" y2="315" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlue5)"/>
        
        <path d="M 700 200 Q 650 260 530 320" stroke="#0ea5e9" stroke-width="3" fill="none" stroke-dasharray="5,3"/>
        <text x="615" y="270" text-anchor="middle" font-size="10" fill="#0ea5e9" font-weight="600">Validate</text>
        
        <!-- Summary -->
        <rect x="80" y="450" width="1040" height="80" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="100" y="475" font-weight="700" fill="#0f172a">Comparative approach:</text>
        <text x="100" y="495" fill="#334155" font-size="12">Study related herpesviruses (RRV, GPHLV, GPXV) to understand host adaptation mechanisms.</text>
        <text x="100" y="510" fill="#334155" font-size="12">Engineer guinea pig-adapted KSHV and EBV strains by modifying receptor binding and immune</text>
        <text x="100" y="525" fill="#334155" font-size="12">evasion genes. Validate tropism, pathogenesis, and therapeutic responses in vivo.</text>
      </svg>
      <div class="diagram-caption">
        Using related herpesviruses (RRV, GPHLV, GPXV) to guide engineering of guinea pig-adapted strains with validation of tropism and pathogenesis.
      </div>
    </figure>

    <!-- Improved Diagram 6: Preclinical Platform -->
    <figure class="research-graphic fade-in">
      <h3>Comprehensive Preclinical Testing Platform</h3>
      <svg class="static-svg" viewBox="0 0 1200 650" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Preclinical testing platform">
        <defs>
          <marker id="arrBlue6" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
          <marker id="arrGreen6" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
          <marker id="arrOrange6" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
          <marker id="arrPurple6" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
          <marker id="arrRed6" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#ef4444"/></marker>
        </defs>
        
        <!-- Central hub -->
        <ellipse cx="600" cy="280" rx="120" ry="80" fill="#dcfce7" stroke="#10b981" stroke-width="3"/>
        <text x="600" y="255" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Guinea Pig</text>
        <text x="600" y="275" text-anchor="middle" font-size="16" font-weight="700" fill="#065f46">Cancer Models</text>
        <text x="600" y="295" text-anchor="middle" font-size="11" fill="#065f46">KSHV • EBV • HPV</text>
        <text x="600" y="310" text-anchor="middle" font-size="11" fill="#065f46">L2C lymphoma</text>
        
        <!-- Therapeutic categories -->
        
        <!-- Antivirals -->
        <rect x="120" y="80" width="150" height="80" rx="12" fill="#dbeafe" stroke="#3b82f6"/>
        <text x="195" y="105" text-anchor="middle" font-size="13" font-weight="700" fill="#1d4ed8">Antivirals</text>
        <text x="195" y="125" text-anchor="middle" font-size="10" fill="#1d4ed8">• Nucleoside analogs</text>
        <text x="195" y="140" text-anchor="middle" font-size="10" fill="#1d4ed8">• Protease inhibitors</text>
        <text x="195" y="155" text-anchor="middle" font-size="10" fill="#1d4ed8">• Entry inhibitors</text>
        
        <!-- Vaccines -->
        <rect x="320" y="60" width="150" height="80" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="395" y="85" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Therapeutic</text>
        <text x="395" y="105" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Vaccines</text>
        <text x="395" y="125" text-anchor="middle" font-size="10" fill="#92400e">• E6/E7 targeting</text>
        <text x="395" y="140" text-anchor="middle" font-size="10" fill="#92400e">• Viral antigens</text>
        
        <!-- Epigenetic modulators -->
        <rect x="950" y="80" width="150" height="80" rx="12" fill="#fee2e2" stroke="#ef4444"/>
        <text x="1025" y="105" text-anchor="middle" font-size="13" font-weight="700" fill="#991b1b">Epigenetic</text>
        <text x="1025" y="125" text-anchor="middle" font-size="13" font-weight="700" fill="#991b1b">Modulators</text>
        <text x="1025" y="145" text-anchor="middle" font-size="10" fill="#991b1b">• HDAC inhibitors</text>
        <text x="1025" y="160" text-anchor="middle" font-size="10" fill="#991b1b">• G4 stabilizers</text>
        
        <!-- Targeted therapies -->
        <rect x="950" y="380" width="150" height="80" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="1025" y="405" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Targeted</text>
        <text x="1025" y="425" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Therapies</text>
        <text x="1025" y="445" text-anchor="middle" font-size="10" fill="#065f46">• BTK inhibitors</text>
        <text x="1025" y="460" text-anchor="middle" font-size="10" fill="#065f46">• Kinase inhibitors</text>
        
        <!-- Immunotherapies -->
        <rect x="320" y="480" width="150" height="80" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
        <text x="395" y="505" text-anchor="middle" font-size="13" font-weight="700" fill="#374151">Immunotherapies</text>
        <text x="395" y="525" text-anchor="middle" font-size="10" fill="#374151">• Checkpoint inhibitors</text>
        <text x="395" y="540" text-anchor="middle" font-size="10" fill="#374151">• Adoptive cell therapy</text>
        <text x="395" y="555" text-anchor="middle" font-size="10" fill="#374151">• mAbs</text>
        
        <!-- Combination therapies -->
        <rect x="120" y="480" width="150" height="80" rx="12" fill="#fef3c7" stroke="#d97706"/>
        <text x="195" y="505" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Combination</text>
        <text x="195" y="525" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Therapies</text>
        <text x="195" y="545" text-anchor="middle" font-size="10" fill="#92400e">• Multi-target</text>
        <text x="195" y="560" text-anchor="middle" font-size="10" fill="#92400e">• Synergistic effects</text>
        
        <!-- Outcomes -->
        <rect x="60" y="280" width="140" height="100" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="130" y="305" text-anchor="middle" font-size="13" font-weight="700" fill="#0f172a">Outcomes</text>
        <text x="130" y="325" text-anchor="middle" font-size="10" fill="#334155">• Viral load</text>
        <text x="130" y="340" text-anchor="middle" font-size="10" fill="#334155">• Tumor burden</text>
        <text x="130" y="355" text-anchor="middle" font-size="10" fill="#334155">• Survival</text>
        <text x="130" y="370" text-anchor="middle" font-size="10" fill="#334155">• Immune activation</text>
        
        <!-- Arrows to central hub -->
        <line x1="270" y1="130" x2="490" y2="220" stroke="#3b82f6" stroke-width="3" marker-end="url(#arrBlue6)"/>
        <line x1="395" y1="140" x2="530" y2="220" stroke="#f59e0b" stroke-width="3" marker-end="url(#arrOrange6)"/>
        <line x1="950" y1="130" x2="700" y2="220" stroke="#ef4444" stroke-width="3" marker-end="url(#arrRed6)"/>
        <line x1="950" y1="430" x2="700" y2="340" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen6)"/>
        <line x1="395" y1="480" x2="530" y2="340" stroke="#6b7280" stroke-width="3" marker-end="url(#arrBlue6)"/>
        <line x1="270" y1="530" x2="490" y2="340" stroke="#d97706" stroke-width="3" marker-end="url(#arrOrange6)"/>
        
        <!-- Outcome connection -->
        <line x1="480" y1="280" x2="205" y2="280" stroke="#cbd5e1" stroke-width="3" marker-end="url(#arrBlue6)"/>
        
        <!-- Summary -->
        <rect x="240" y="580" width="720" height="50" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="260" y="600" font-weight="700" fill="#0f172a">Platform integration:</text>
        <text x="260" y="615" fill="#334155" font-size="11">Comprehensive therapeutic evaluation across multiple modalities using guinea pig viral cancer models with standardized outcomes.</text>
      </svg>
      <div class="diagram-caption">
        Integrated platform testing antivirals, vaccines, epigenetic modulators, targeted and immune therapies with standardized outcome measures.
      </div>
    </figure>

    <!-- Improved Diagram 7: Single-cell Genomics -->
    <figure class="research-graphic fade-in">
      <h3>Single-cell Genomics and Systems Biology Approaches</h3>
      <svg class="static-svg" viewBox="0 0 1200 650" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Single-cell genomics workflow">
        <defs>
          <marker id="arrBlue7" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#3b82f6"/></marker>
          <marker id="arrGreen7" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#10b981"/></marker>
          <marker id="arrOrange7" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#f59e0b"/></marker>
          <marker id="arrPurple7" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0L10 5L0 10Z" fill="#8b5cf6"/></marker>
        </defs>
        
        <!-- Tissue sample -->
        <rect x="60" y="120" width="140" height="80" rx="12" fill="#f1f5f9" stroke="#6b7280"/>
        <text x="130" y="145" text-anchor="middle" font-size="14" font-weight="700" fill="#374151">Tumor Tissue</text>
        <text x="130" y="165" text-anchor="middle" font-size="11" fill="#374151">Mixed populations:</text>
        <text x="130" y="180" text-anchor="middle" font-size="10" fill="#374151">Tumor • Immune • Stroma</text>
        
        <!-- Single cell dissociation -->
        <rect x="240" y="120" width="120" height="80" rx="12" fill="#ecfdf5" stroke="#10b981"/>
        <text x="300" y="145" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Cell</text>
        <text x="300" y="165" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Dissociation</text>
        <text x="300" y="185" text-anchor="middle" font-size="10" fill="#065f46">Single cell suspension</text>
        
        <!-- 10X workflow -->
        <rect x="400" y="120" width="140" height="80" rx="12" fill="#fae8ff" stroke="#8b5cf6"/>
        <text x="470" y="145" text-anchor="middle" font-size="13" font-weight="700" fill="#6b21a8">10X Genomics</text>
        <text x="470" y="165" text-anchor="middle" font-size="13" font-weight="700" fill="#6b21a8">scRNA-seq</text>
        <text x="470" y="185" text-anchor="middle" font-size="10" fill="#6b21a8">Cell barcoding + UMI</text>
        
        <!-- Analysis pipeline -->
        <rect x="580" y="100" width="180" height="120" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
        <text x="670" y="125" text-anchor="middle" font-size="13" font-weight="700" fill="#075985">Data Analysis</text>
        
        <rect x="600" y="140" width="60" height="20" rx="5" fill="#bae6fd" stroke="#0ea5e9"/>
        <text x="630" y="153" text-anchor="middle" font-size="9" font-weight="600" fill="#075985">QC Filter</text>
        
        <rect x="670" y="140" width="70" height="20" rx="5" fill="#bae6fd" stroke="#0ea5e9"/>
        <text x="705" y="153" text-anchor="middle" font-size="9" font-weight="600" fill="#075985">Normalize</text>
        
        <rect x="600" y="170" width="60" height="20" rx="5" fill="#bae6fd" stroke="#0ea5e9"/>
        <text x="630" y="183" text-anchor="middle" font-size="9" font-weight="600" fill="#075985">Cluster</text>
        
        <rect x="670" y="170" width="70" height="20" rx="5" fill="#bae6fd" stroke="#0ea5e9"/>
        <text x="705" y="183" text-anchor="middle" font-size="9" font-weight="600" fill="#075985">UMAP</text>
        
        <rect x="600" y="200" width="140" height="15" rx="5" fill="#bae6fd" stroke="#0ea5e9"/>
        <text x="670" y="210" text-anchor="middle" font-size="9" font-weight="600" fill="#075985">Cell Type ID</text>
        
        <!-- Cell type results -->
        <rect x="800" y="100" width="160" height="120" rx="12" fill="#dcfce7" stroke="#10b981"/>
        <text x="880" y="125" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Cell Populations</text>
        
        <circle cx="820" cy="145" r="6" fill="#ef4444"/>
        <text x="835" y="150" font-size="10" fill="#065f46">Tumor cells</text>
        
        <circle cx="820" cy="160" r="6" fill="#3b82f6"/>
        <text x="835" y="165" font-size="10" fill="#065f46">CD8+ T cells</text>
        
        <circle cx="820" cy="175" r="6" fill="#f59e0b"/>
        <text x="835" y="180" font-size="10" fill="#065f46">CD4+ T cells</text>
        
        <circle cx="820" cy="190" r="6" fill="#8b5cf6"/>
        <text x="835" y="195" font-size="10" fill="#065f46">B cells</text>
        
        <circle cx="820" cy="205" r="6" fill="#6b7280"/>
        <text x="835" y="210" font-size="10" fill="#065f46">Macrophages</text>
        
        <!-- Pathway analysis -->
        <rect x="80" y="300" width="180" height="100" rx="12" fill="#fff7ed" stroke="#fb923c"/>
        <text x="170" y="325" text-anchor="middle" font-size="13" font-weight="700" fill="#9a3412">Pathway Analysis</text>
        <text x="170" y="345" text-anchor="middle" font-size="10" fill="#9a3412">• GSEA enrichment</text>
        <text x="170" y="360" text-anchor="middle" font-size="10" fill="#9a3412">• Viral gene programs</text>
        <text x="170" y="375" text-anchor="middle" font-size="10" fill="#9a3412">• Host immune responses</text>
        <text x="170" y="390" text-anchor="middle" font-size="10" fill="#9a3412">• Cell-cell communication</text>
        
        <!-- Spatial validation -->
        <rect x="300" y="300" width="180" height="100" rx="12" fill="#ecfdf5" stroke="#10b981"/>
        <text x="390" y="325" text-anchor="middle" font-size="13" font-weight="700" fill="#065f46">Spatial Validation</text>
        <text x="390" y="345" text-anchor="middle" font-size="10" fill="#065f46">• Immunohistochemistry</text>
        <text x="390" y="360" text-anchor="middle" font-size="10" fill="#065f46">• In situ hybridization</text>
        <text x="390" y="375" text-anchor="middle" font-size="10" fill="#065f46">• Tissue architecture</text>
        <text x="390" y="390" text-anchor="middle" font-size="10" fill="#065f46">• Biomarker validation</text>
        
        <!-- Systems integration -->
        <rect x="520" y="300" width="180" height="100" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
        <text x="610" y="325" text-anchor="middle" font-size="13" font-weight="700" fill="#92400e">Systems Integration</text>
        <text x="610" y="345" text-anchor="middle" font-size="10" fill="#92400e">• Multi-omics analysis</text>
        <text x="610" y="360" text-anchor="middle" font-size="10" fill="#92400e">• Network modeling</text>
        <text x="610" y="375" text-anchor="middle" font-size="10" fill="#92400e">• Drug synergy prediction</text>
        <text x="610" y="390" text-anchor="middle" font-size="10" fill="#92400e">• Biomarker discovery</text>
        
        <!-- Disease applications -->
        <rect x="740" y="300" width="180" height="100" rx="12" fill="#f3e8ff" stroke="#8b5cf6"/>
        <text x="830" y="325" text-anchor="middle" font-size="13" font-weight="700" fill="#6b21a8">Model Applications</text>
        
        <rect x="760" y="345" width="40" height="15" rx="3" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="780" y="355" text-anchor="middle" font-size="8" font-weight="600" fill="#6b21a8">KSHV</text>
        
        <rect x="810" y="345" width="40" height="15" rx="3" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="830" y="355" text-anchor="middle" font-size="8" font-weight="600" fill="#6b21a8">HPV</text>
        
        <rect x="860" y="345" width="40" height="15" rx="3" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="880" y="355" text-anchor="middle" font-size="8" font-weight="600" fill="#6b21a8">L2C</text>
        
        <rect x="760" y="370" width="140" height="15" rx="3" fill="#ede9fe" stroke="#8b5cf6"/>
        <text x="830" y="380" text-anchor="middle" font-size="8" font-weight="600" fill="#6b21a8">Therapeutic responses</text>
        
        <!-- Flow arrows -->
        <line x1="200" y1="160" x2="235" y2="160" stroke="#6b7280" stroke-width="3" marker-end="url(#arrBlue7)"/>
        <line x1="360" y1="160" x2="395" y2="160" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen7)"/>
        <line x1="540" y1="160" x2="575" y2="160" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurple7)"/>
        <line x1="760" y1="160" x2="795" y2="160" stroke="#0ea5e9" stroke-width="3" marker-end="url(#arrBlue7)"/>
        
        <!-- Analysis connections -->
        <line x1="670" y1="220" x2="170" y2="295" stroke="#fb923c" stroke-width="3" marker-end="url(#arrOrange7)"/>
        <line x1="670" y1="220" x2="390" y2="295" stroke="#10b981" stroke-width="3" marker-end="url(#arrGreen7)"/>
        <line x1="670" y1="220" x2="610" y2="295" stroke="#f59e0b" stroke-width="3" marker-end="url(#arrOrange7)"/>
        <line x1="880" y1="220" x2="830" y2="295" stroke="#8b5cf6" stroke-width="3" marker-end="url(#arrPurple7)"/>
        
        <!-- Cross-validation connections -->
        <path d="M 260 350 Q 280 280 390 300" stroke="#10b981" stroke-width="2" fill="none" stroke-dasharray="4,2"/>
        <path d="M 480 350 Q 560 280 610 300" stroke="#f59e0b" stroke-width="2" fill="none" stroke-dasharray="4,2"/>
        
        <!-- Summary -->
        <rect x="80" y="460" width="840" height="80" rx="12" fill="#f8fafc" stroke="#cbd5e1"/>
        <text x="100" y="485" font-weight="700" fill="#0f172a">Integrated workflow:</text>
        <text x="100" y="505" fill="#334155" font-size="12">From tissue dissociation to single-cell sequencing, clustering, and pathway analysis.</text>
        <text x="100" y="520" fill="#334155" font-size="12">Results validated through spatial methods (IHC, ISH) and integrated with systems</text>
        <text x="100" y="535" fill="#334155" font-size="12">approaches for biomarker discovery across KSHV, HPV, and lymphoma models.</text>
      </svg>
      <div class="diagram-caption">
        Comprehensive single-cell workflow from tissue to pathway analysis with spatial validation and systems integration across disease models.
      </div>
    </figure>

    <p class="fade-in">
      Together, these efforts define a comprehensive program in <strong>viral oncology</strong>:
      connecting molecular mechanisms of viral pathogenesis to clinically relevant animal models
      across herpesvirus and papillomavirus systems. By expanding the guinea pig as a small-animal
      model for KSHV/EBV-associated cancers and HPV cervical cancer, we aim to deliver practical
      tools for understanding—and ultimately intervening in—the full spectrum of virus-associated cancers.
    </p>

  </main>

  <footer class="site-footer" role="contentinfo">
    <div class="container footer-grid">
      <div class="footer-brand">
        <img src="assets/stanfield-lab-icon.svg" alt="Stanfield Lab icon" class="footer-logo">
        <div>
          <h3>Stanfield Lab</h3>
          <p>Viral Oncology • Guinea-pig models of virus-associated cancers</p>
        </div>
      </div>
      <div>
        <h4>Find us</h4>
        <p>
          <a href="https://www.lsu.edu/vetmed/index.php" target="_blank" rel="noopener">LSU School of Veterinary Medicine</a><br>
          Baton Rouge, LA 70803
        </p>
      </div>
      <div>
        <h4>Contact</h4>
        <p><a href="mailto:bstanf5@lsu.edu">bstanf5@lsu.edu</a></p>
      </div>
    </div>
    <div class="container footer-bottom">
      <p>© <span id="year"></span> Stanfield Lab • LSU SVM</p>
    </div>
  </footer>

  <script>
    // Mobile navigation
    document.getElementById('navToggle').addEventListener('click', function() {
      const nav = document.getElementById('primaryNav');
      const isExpanded = this.getAttribute('aria-expanded') === 'true';
      this.setAttribute('aria-expanded', !isExpanded);
      nav.classList.toggle('active');
    });

    // Simple scroll animation
    function handleScrollAnimation() {
      const elements = document.querySelectorAll('.fade-in');
      elements.forEach(el => {
        const top = el.getBoundingClientRect().top;
        if (top < window.innerHeight - 150) el.classList.add('visible');
      });
    }
    window.addEventListener('scroll', handleScrollAnimation);
    handleScrollAnimation();

    // Year
    document.getElementById('year').textContent = new Date().getFullYear();

    // Theme toggle placeholder
    document.getElementById('themeToggle').addEventListener('click', function() {
      document.documentElement.classList.toggle('dark');
    });
  </script>

</body>
</html>
